The Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the approval of Abbvie’s oral therapy Maviret…
Articles by Marisa Wexler, MS
Nearly one in five people with chronic hepatitis B who were given add-on treatment with GlaxoSmithKline (GSK)’s bepirovirsen…
Gilead Sciences‘ Livdelzi (seladelpar) effectively reduces blood levels of alkaline phosphatase (ALP), a key marker of liver damage, in…
Treatment with Wegovy (semaglutide) showed a consistent safety and efficacy profile across a range of patient subgroups with metabolic…
Treatment with Livmarli (maralixibat) can reduce cholesterol levels and help clear fatty skin growths called xanthomas in children with…
PBGENE-HBV, Precision Biosciences’ experimental gene-editing therapy for chronic hepatitis B, showed early evidence of eliminating and inactivating hepatitis…
Belapectin, Galectin Therapeutics’ investigational therapy, significantly reduced the development of new enlarged blood vessels in the esophagus among people…
Due to itching at nighttime, children with Alagille syndrome often experience substantial problems getting a good night’s sleep, leading…
GlaxoSmithKline (GSK) has submitted an application to Health Canada seeking approval of its chronic hepatitis B therapy bepirovirsen…
Madrigal Pharmaceuticals has secured worldwide rights to develop ARO-PNPLA3, an experimental treatment created by Arrowhead Pharmaceuticals for people…